This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through September 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Northern Technologies (NTIC) Misses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Northern Technologies (NTIC) delivered earnings and revenue surprises of -44.44% and 10.44%, respectively, for the quarter ended February 2023. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Hold Onto Chemours (CC) Stock for Now
by Zacks Equity Research
While Chemours (CC) is exposed to headwinds from higher raw material costs, it gains on healthy Opteon demand and its pricing actions.
Chemours (CC) Posts Break-Even Q4 Earnings, Sales Miss
by Zacks Equity Research
Chemours (CC) gains from increased prices across its segments amid headwinds from higher input cost inflation, adverse currency movements and soft demand in Europe & Asia in Q4.
Chemours (CC) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Chemours (CC) give a sense of how the business performed in the quarter ended December 2022, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Chemours (CC) Reports Break-Even Earnings for Q4
by Zacks Equity Research
Chemours (CC) delivered earnings and revenue surprises of -100% and 5.93%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
FMC (FMC) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
FMC (FMC) delivered earnings and revenue surprises of 2.16% and 7.86%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Chemours (CC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Chemours (CC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Chemours (CC) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Chemours (CC) stock based on the movements in the options market lately.
Albemarle (ALB) Up 0.3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Albemarle (ALB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Chemours (CC) Gains on Opteon Demand Amid Input Cost Woes
by Zacks Equity Research
While Chemours (CC) is exposed to headwinds from higher raw material costs, it gains on healthy Opteon demand, strong execution and its cost-reduction and pricing actions.
Chemours (CC) Earnings and Revenues Top Estimates in Q3
by Zacks Equity Research
Higher prices contribute favorably to Chemours' (CC) top line growth in the third quarter.
New Strong Sell Stocks for October 26th
by Zacks Equity Research
HES, JRVR and CC have been added to the Zacks Rank #5 (Strong Sell) List on October 26, 2022.
Chemours (CC) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Chemours (CC) delivered earnings and revenue surprises of 6.90% and 0.31%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Chemours (CC) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Chemours (CC) closed at $28.77 in the latest trading session, marking a -1.34% move from the prior day.
Earnings Preview: Methanex (MEOH) Q3 Earnings Expected to Decline
by Zacks Equity Research
Methanex (MEOH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Chemours (CC) to Post Q3 Earnings: What's in the Offing?
by Zacks Equity Research
While Chemours (CC) is likely to have benefited from healthy demand and pricing actions, raw material inflation and ore logistics constraints are expected to have affected its performance.
Earnings Preview: Chemours (CC) Q3 Earnings Expected to Decline
by Zacks Equity Research
Chemours (CC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Chemours (CC) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Chemours (CC) closed the most recent trading day at $26.53, moving -1.38% from the previous trading session.
Chemours (CC) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Chemours (CC) closed the most recent trading day at $24.50, moving +1.66% from the previous trading session.
Are Options Traders Betting on a Big Move in Chemours (CC) Stock?
by Zacks Equity Research
Investors need to pay close attention to Chemours (CC) stock based on the movements in the options market lately.
Chemours (CC) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Chemours (CC) closed the most recent trading day at $24.10, moving +0.67% from the previous trading session.
Here's Why You Should Hold Onto Chemours (CC) Stock for Now
by Zacks Equity Research
While Chemours (CC) is exposed to supply-chain issues and higher input costs, it gains on healthy demand, strong execution and its cost-reduction and pricing actions.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Company News for Sep 22, 2022
by Zacks Equity Research
Companies in The News Are: GIS,BYND,COTY,CC
FMC Corp (FMC) Gains on Strong Demand Amid Cost Headwinds
by Zacks Equity Research
FMC Corp (FMC) benefits from higher demand for its products, its portfolio strength and contributions of new products amid currency and input cost headwinds.